1
Sheldon Hiebert, Michael S Bowsher, Ramkumar Rajamani, Rongti Li, Paul Michael Scola: Hepatitis C virus inhibitors. Bristol Myers Squibb Company, Pamela A Mingo, Mary K VanAtten, October 22, 2013: US08563505 (2 worldwide citation)

Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.


2

3
Sheldon Hiebert, Ramkumar Rajamani, Li Qiang Sun, Eric Mull, Eric P Gillis, Michael S Bowsher, Qian Zhao, Nicholas A Meanwell, Kishore V Renduchintala, Kandhasamy Sarkunam, Pulicharla Nagalakshmi, P V K Suresh Babu, Paul Michael Scola: Hepatitis C virus inhibitors. Bristol Myers Squibb Company, Pamela A Mingo, February 17, 2015: US08957203 (1 worldwide citation)

Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.


4
Li Qiang Sun, Eric P Gillis, Eric Mull, Michael S Bowsher, Qian Zhao, Paul Michael Scola: Hepatitis C virus inhibitors. Bristol Myers Squibb Company, Pamela A Mingo, March 21, 2017: US09598433

Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.


5
Eric P Gillis, Michael S Bowsher, Paul Michael Scola: Hepatitis C virus inhibitors. Bristol Myers Squibb Company, Pamela A Mingo, May 10, 2016: US09334279

Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.


6
Sheldon Hiebert, Ramkumar Rajamani, Li Qiang Sun, Eric Mull, Eric P Gillis, Michael S Bowsher, Qian Zhao, Nicholas A Meanwell, Kishore V Renduchintala, Kandhasamy Sarkunam, Pulicharla Nagalakshmi, P V K Suresh Babu, Paul Michael Scola: Hepatitis C virus inhibitors. Bristol Myers Squibb Company, Pamela A Mingo, December 27, 2016: US09527885

Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.


7
Alexandre L Heureux, Sheldon Hiebert, Carol Hu, Patrick Y S Lam, John Lloyd, Zulan Pi, Jennifer X Qiao, Carl Thibeault, George O Tora, Wu Yang, Yufeng Wang, Tammy C Wang, Michael S Bowsher, Ruel Rejean: receptor, 7-hydroxy-indolinyl antagonists of P2Y. Bristol Myers Squibb Company, Barry Jacobsen, January 10, 2017: US09540323

The present invention provides compounds of Formula (I): Formula (I) as defined in the specification and compositions comprising any of such novel compounds. These compounds are antagonists of P2Y1 receptor which may be used medicaments.


8
Yasutsuga Ueda, Timothy P Connolly, Barry L Johnson, Chen Li, B Narasimhulu Naidu, Manoj Patel, Kevin Peese, Margaret E Sorenson, Michael A Walker, Michael S Bowsher, Rongti Li: HIV integrase inhibitors. Bristol Myers Squibb Company, James Epperson, September 16, 2014: US08835411

The disclosure generally relates to the novel compounds of formula I, including their salts, which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical composition ...


9
Sheldon Hiebert, Ramkumar Rajamani, Michael S Bowsher, Rongti Li, Paul Michael Scola: Hepatitis C Virus Inhibitors. Bristol Myers Squibb Company, Louis J Wille, Bristol Myers Squibb Company, April 1, 2010: US20100080770-A1

Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.


10
Sheldon Hiebert, Michael S Bowsher, Ramkumar Rajamani, Rongti Li, Paul Michael Scola: Hepatitis C Virus Inhibitors. Bristol Myers Squibb Company, Louis J Wille, Bristol Myers Squibb Company, April 1, 2010: US20100080771-A1

Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.